P16 as a molecular biomarker of cervical adenocarcinoma
- 31 March 2004
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 190 (3) , 668-673
- https://doi.org/10.1016/j.ajog.2003.09.038
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Endocervical glandular lesions: controversial aspects and ancillary techniquesJournal of Clinical Pathology, 2003
- Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo‐endometrial metaplasia, endometriosis and microglandular hyperplasiaHistopathology, 2002
- ThinPrep detection of cervical and endometrial adenocarcinomaCancer, 2002
- Cell Cycle Aberrations in the Pathogenesis of Squamous Cell Carcinoma of the Uterine CervixGynecologic Oncology, 2001
- Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomasVirchows Archiv, 2001
- Early invasive adenocarcinoma of the cervixCancer, 2000
- The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based StudyGynecologic Oncology, 2000
- ThinPrep® pap test promotes detection of glandular lesions of the endocervixDiagnostic Cytopathology, 2000
- Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervixCancer, 1998
- International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomasInternational Journal of Cancer, 1998